#METABOLOMICS WORKBENCH atbowers_20220809_072658 DATATRACK_ID:3400 STUDY_ID:ST002249 ANALYSIS_ID:AN003675 VERSION 1 CREATED_ON 08-24-2022 #PROJECT PR:PROJECT_TITLE Sex-dependent effects of FGF21 on hepatic metabolism PR:PROJECT_SUMMARY Untargeted metabolomics analysis of livers from male and female mice PR:PROJECT_SUMMARY administered FGF21 or saline vehicle. PR:INSTITUTE University of California, Davis PR:LAST_NAME Chaffin PR:FIRST_NAME Aki PR:ADDRESS 1 Shields Ave PR:EMAIL atchaffin@ucdavis.edu PR:PHONE 603-359-1907 PR:PUBLICATIONS https://doi.org/10.1172/jci.insight.155848 PR:DOI http://dx.doi.org/10.21228/M8ZX31 #STUDY ST:STUDY_TITLE Sex-dependent effects of FGF21 on hepatic metabolism ST:STUDY_SUMMARY To investigate sex-dependent effects of fibroblast growth factor-21 (FGF21), ST:STUDY_SUMMARY diet-induced obese male and female wildtype mice were administered two acute ST:STUDY_SUMMARY doses of FGF21 or saline vehicle. Mice were euthanized, livers collected, and ST:STUDY_SUMMARY submitted for untargeted metabolomics analysis. ST:INSTITUTE University of California, Davis ST:DEPARTMENT Neurobiology, Physiology and Behavior ST:LABORATORY Ryan ST:LAST_NAME Chaffin ST:FIRST_NAME Aki ST:ADDRESS 1 Shields Ave ST:EMAIL atchaffin@ucdavis.edu ST:PHONE 603-359-1907 ST:SUBMIT_DATE 2022-08-09 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Mus musculus SU:TAXONOMY_ID 10090 SU:GENOTYPE_STRAIN C57BL/6J SU:GENDER Male and female SU:ANIMAL_LIGHT_CYCLE 12:12 SU:ANIMAL_FEED 60% high-fat diet (Research Diets Cat# D12492) #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 23 23_016 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa23_1.cdf SUBJECT_SAMPLE_FACTORS 27 27_004 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa30_1.cdf SUBJECT_SAMPLE_FACTORS 28 28_024 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa44_1.cdf SUBJECT_SAMPLE_FACTORS 30 30_020 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180824bJWsa01_1.cdf SUBJECT_SAMPLE_FACTORS 34 34_028 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa47_1.cdf SUBJECT_SAMPLE_FACTORS 37 37_036 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa37_1.cdf SUBJECT_SAMPLE_FACTORS 38 38_012 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa49_1.cdf SUBJECT_SAMPLE_FACTORS 40 40_008 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa15_1.cdf SUBJECT_SAMPLE_FACTORS 41 41_032 Sex:Female | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa40_1.cdf SUBJECT_SAMPLE_FACTORS 24 24_023 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa16_1.cdf SUBJECT_SAMPLE_FACTORS 25 25_035 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa45_1.cdf SUBJECT_SAMPLE_FACTORS 26 26_019 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa38_1.cdf SUBJECT_SAMPLE_FACTORS 29 29_011 Sex:Female | Treatment:Saline RAW_FILE_NAME=180824bJWsa03_1.cdf SUBJECT_SAMPLE_FACTORS 31 31_003 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa25_1.cdf SUBJECT_SAMPLE_FACTORS 32 32_039 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa33_1.cdf SUBJECT_SAMPLE_FACTORS 33 33_015 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa27_1.cdf SUBJECT_SAMPLE_FACTORS 35 35_031 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa34_1.cdf SUBJECT_SAMPLE_FACTORS 36 36_027 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa19_1.cdf SUBJECT_SAMPLE_FACTORS 39 39_007 Sex:Female | Treatment:Saline RAW_FILE_NAME=180823bJWsa20_1.cdf SUBJECT_SAMPLE_FACTORS 10 10_022 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180824bJWsa02_1.cdf SUBJECT_SAMPLE_FACTORS 1 1_034 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa24_1.cdf SUBJECT_SAMPLE_FACTORS 13 13_041 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa43_1.cdf SUBJECT_SAMPLE_FACTORS 14 14_038 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa18_1.cdf SUBJECT_SAMPLE_FACTORS 17 17_010 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa26_1.cdf SUBJECT_SAMPLE_FACTORS 18 18_018 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa17_1.cdf SUBJECT_SAMPLE_FACTORS 21 21_002 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa35_1.cdf SUBJECT_SAMPLE_FACTORS 22 22_026 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa21_1.cdf SUBJECT_SAMPLE_FACTORS 3 3_030 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa28_1.cdf SUBJECT_SAMPLE_FACTORS 7 7_006 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa46_1.cdf SUBJECT_SAMPLE_FACTORS 8 8_014 Sex:Male | Treatment:FGF21 RAW_FILE_NAME=180823bJWsa14_1.cdf SUBJECT_SAMPLE_FACTORS 11 11_025 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa22_1.cdf SUBJECT_SAMPLE_FACTORS 12 12_013 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa48_1.cdf SUBJECT_SAMPLE_FACTORS 15 15_009 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa42_1.cdf SUBJECT_SAMPLE_FACTORS 16 16_029 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa13_1.cdf SUBJECT_SAMPLE_FACTORS 19 19_040 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa39_1.cdf SUBJECT_SAMPLE_FACTORS 20 20_005 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa31_1.cdf SUBJECT_SAMPLE_FACTORS 2 2_037 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa50_1.cdf SUBJECT_SAMPLE_FACTORS 4 4_017 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa41_1.cdf SUBJECT_SAMPLE_FACTORS 5 5_021 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa29_1.cdf SUBJECT_SAMPLE_FACTORS 6 6_033 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa32_1.cdf SUBJECT_SAMPLE_FACTORS 9 9_001 Sex:Male | Treatment:Saline RAW_FILE_NAME=180823bJWsa36_1.cdf #COLLECTION CO:COLLECTION_SUMMARY Mice were euthanized and livers collected and frozen in liquid N2. CO:SAMPLE_TYPE Liver CO:STORAGE_CONDITIONS -80℃ #TREATMENT TR:TREATMENT_SUMMARY Male and female C57BL/6J mice were placed on 60% high-fat diet (Research Diets, TR:TREATMENT_SUMMARY Cat# D12492) for approx. 10 weeks beginning at 10 weeks of age. Mice were then TR:TREATMENT_SUMMARY counterbalanced into two treatment groups based on body weight (n = 9-11 mice/ TR:TREATMENT_SUMMARY sex/ treatment). For experiment, one dose of FGF21 (0.1 mg/kg, ip) or saline TR:TREATMENT_SUMMARY vehicle was given right before the onset of the dark cycle, then another dose TR:TREATMENT_SUMMARY (0.1 mg/kg, ip) was given the following morning after the onset of the light TR:TREATMENT_SUMMARY cycle. Mice were euthanized two hours following the AM injection, livers TR:TREATMENT_SUMMARY collected, and frozen in liquid N2. TR:TREATMENT_COMPOUND recombinant human FGF21 (ProSpecBio, Cat# CYT-474) TR:TREATMENT_ROUTE intraperitoneal injection TR:TREATMENT_DOSE 0.1 mg/kg TR:TREATMENT_DOSEVOLUME 0.01 mg/mL TR:TREATMENT_VEHICLE saline #SAMPLEPREP SP:SAMPLEPREP_SUMMARY See attached file. SP:SAMPLEPREP_PROTOCOL_ID methods_sampleprep.pdf SP:SAMPLEPREP_PROTOCOL_FILENAME methods_sampleprep.pdf #CHROMATOGRAPHY CH:METHODS_FILENAME methods_GC.pdf CH:INSTRUMENT_NAME Agilent 7890A CH:COLUMN_NAME Restek Rtx-5Sil MS (30 x 0.25mm, 0.25um) CH:CHROMATOGRAPHY_TYPE GC #ANALYSIS AN:ANALYSIS_TYPE MS AN:ANALYSIS_PROTOCOL_FILE methods_dataprocessing.pdf #MS MS:INSTRUMENT_NAME Agilent 7890A MS:INSTRUMENT_TYPE GC-TOF MS:MS_TYPE EI MS:MS_COMMENTS See attached file. MS:ION_MODE POSITIVE MS:MS_RESULTS_FILE ST002249_AN003675_Results.txt UNITS:peak Has m/z:Yes #END